Aegle Therapeutics ^Company

Aegle Therapeutics is a biotechnology company that is developing a new therapy using extracellular vesicles, including exosomes, from allogeneic bone marrow-derived mesenchymal stem cells. Their technology is being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skin blistering disorder. The company's proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle's EV therapy has the potential to enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company was founded in 2013 and is based in Miami, Florida.